Cyprotex is pleased to announce that it has been chosen to work with the National Institutes of Health Chemical Genomics Centre (NCGC), based in Rockville, Maryland USA.
The NCGC has been established by the National Institute of Health, with a view to creating a national resource in chemical probe development. The centre uses the latest industrial-scale technologies in order to collect data for defining the cross-section between chemical space and biological activity.
Cyprotex's automated facilities satisfy the NCGC's requirements by providing exceptionally robust data and rapid turnaround while profiling the in vitro properties of a wide range of compounds.
The data generated by Cyprotex will then be published on the PubChem website(http://pubchem.ncbi.nlm.nih.gov/), a National Centre for Biotechnology Information (NCBI) program providing public information on the biological activities of small molecules.
Commenting on the agreement, Robert Morrison Atwater, CEO of Cyprotex plc said: "We are looking forward to initiating this new relationship with NIH and are delighted that Cyprotex has been chosen as their partner for this valuable and exciting project."
Cyprotex is a specialist provider of ADME (Absorption, Distribution, Metabolism and Excretion) screening and predictive services. Its unique Cloe� technology, based on a highly automated laboratory and IT software platform, ensures optimal performance and quality of our services for our clients. This is now being recognised within the industry leading to a rapid expansion of our customer base.
For further information:
Helen Gill PhD, Product Development Manager
Tel: +44 (0)1625 505 100